Skip to main content
Clinical Trials/ACTRN12605000206628
ACTRN12605000206628
Recruiting
Phase 2

Randomised controlled trial of five treatments for women with breakthrough bleeding while using Implanon hormonal contraception to treat breakthrough bleeding (treatments options: placebo; mifepristone plus ethinyl oestradiol; doxycycline; doxycycline plus ethinyl oestradiol; doxycycline plus mifepristone)

FPA Health, 328 Liverpool Rd Ashfield NSW 21310 sites500 target enrollmentAugust 25, 2005

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Breakthrough bleeding with Implanon progestogen-only contraception
Sponsor
FPA Health, 328 Liverpool Rd Ashfield NSW 2131
Enrollment
500
Status
Recruiting
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 25, 2005
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
Female

Investigators

Sponsor
FPA Health, 328 Liverpool Rd Ashfield NSW 2131

Eligibility Criteria

Inclusion Criteria

  • Implanon users, with a complaint of episodes of prolonged (7 days or greater) or frequent (bleeding\-free intervals of less than 15 days) bleeding. Women who are willing to participate in a research investigation of new approaches to the therapy of breakthrough bleeding.

Exclusion Criteria

  • Women with contraindications to the use of oestrogen, anti\-progesterone or tetracycline therapy; women with allergy to lactose; women who are unwilling to keep a daily menstrual diary or otherwise unwilling to follow the study criteria.

Outcomes

Primary Outcomes

Not specified

Similar Trials